Clinical Trials Browser

Phase 1/2 × NETWORK × Erlotinib Hydrochloride × Clear all

NCT01068587 2023-08-04

MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms